Evoke Pharma appoints co-founder Matthew D'Onofrio as CEO, succeeding Dave Gonyer effective March 31, 2024

Evoke Pharma Inc

Dave A. Gonyer resigns as CEO and Board member effective March 31, 2024 for personal reasons; no disagreement with Company.
Matthew J. D'Onofrio appointed CEO and Board member effective March 31, 2024.
D'Onofrio is co-founder, previously President, COO, Secretary and Treasurer since February 2023.
No family relationships or material interests in transactions requiring disclosure.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dave A. Gonyer

Chief Executive Officer

Evoke Pharma Inc

Effective: 2024-03-31
Successor: Matthew J. D'Onofrio
Filed: March 21, 2024, 7:59 PM ET

who is resigning effective as of March 31, 2024, for personal reasons.

Appointed

Matthew J. D'Onofrio

Chief Executive Officer

Evoke Pharma Inc

Effective: 2024-03-31
Filed: March 21, 2024, 7:59 PM ET

appointed Matthew J. D’Onofrio as the Company’s Chief Executive Officer, effective as of March 31, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dave A. Gonyer resigned as Chief Executive Officer at Evoke Pharma Inc.

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

who is resigning effective as of March 31, 2024, for personal reasons.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew J. D'Onofrio was appointed as Chief Executive Officer at Evoke Pharma Inc.

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

appointed Matthew J. D’Onofrio as the Company’s Chief Executive Officer, effective as of March 31, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0000950170-24-034708

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.